Mirabegron has been shown to cause relaxation of the isolated mouse urethra, partly through blockade of α1A-adrenoceptors and α1D-adrenoceptors. However, although this effect might be an interesting pharmacological in vitro observation, it seems to have no relevance for the clinical use of mirabegron in the treatment of the overactive bladder.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Igawa, Y. & Michel, M. C. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn-Schmiedebergs Arch. Pharmacol. 386, 177–183 (2013).
Gillespie, J. I., Rouget, C., Palea, S., Granato, C. & Korstanje, C. Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction. Naunyn-Schmiedebergs Arch. Pharmacol. 388, 719–726 (2015).
D'Agostino, G., Condino, A. M., Calvi, P. Involvement of β3-adrenoceptors in the inhibitory control 3 of cholinergic activity in human bladder: direct evidence by [3H]-acetylcholine release experiments in the isolated detrusor. Eur. J. Pharmacol. 758, 115–122 (2015).
Alexandre, E. C. et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade. Br. J. Pharmacol. http://dx.doi.org/10.1111/bph.13367 (2015).
Taki, N., Taniguchi, T., Okada, K., Moriyama, N. & Muramatsu, I. Evidence for predominant mediation of α1-adrenoceptor in the tonus of entire urethra of women. J. Urol. 162, 1829–1832 (1999).
Rosa, G. M. et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.09.007 (2015).
Nitti, V. W. et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J. Urol. 190, 1320–1327 (2013).
Matsukawa, Y., Takai, S., Funahashi, Y., Yamamoto, T. & Gotoh, M. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology 85, 786–790 (2015).
Robinson, D. et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 100, 840–845 (2007).
Reitz, A. et al. The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur. Urol. 46, 235–240 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K-E.A. declares that he is a consultant and/or on the advisory board for Allergan, Astellas and Ferring.
Rights and permissions
About this article
Cite this article
Andersson, KE. On the mode of action of mirabegron. Nat Rev Urol 13, 131–132 (2016). https://doi.org/10.1038/nrurol.2015.297
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.297
